Category Archives: startup

Establishing markets in prevention and wellness – 3 examples

1. AIA Vitality Life Insurance

  • https://www.aiavitality.com.au/vmp-au/
  • Wendy Brown – University of Queensland wbrown@hms.uq.edu.au
  • Tracy Kolbe-Alexander – University of Queensland

2. Data Driven Healthcare Quality Markets

3. Abu Dhabi Health Authority – Weqaya

 

 

Vitality Institute Commission – Recommendation 3 http://thevitalityinstitute.org/commission/create-markets-for-health/

The Vitality Institute: Investing In Prevention – A National Imperetive

Vitality absolutely smash it across the board…

  • Investment
  • Leadership
  • Market Creation
  • Developing Health Metrics
  • Everything…!

Must get on to these guys…..

PDF: Vitality_Recommendations2014_Report

PDF: InvestingInPrevention_Slides

Presentation: https://goto.webcasts.com/viewer/event.jsp?ei=1034543 (email: blackfriar@gmail.com)

 

From Forbes: http://www.forbes.com/sites/brucejapsen/2014/06/18/how-corporate-america-could-save-300-billion-by-measuring-health-like-financial-performance/

Bruce Japsen, Contributor

I write about health care and policies from the president’s hometown

How Corporate America Could Save $300 Billion By Measuring Health Like Financial Performance

The U.S. could save more than $300 billion annually if employers adopted strategies that promoted health, prevention of chronic disease and measured progress of “working-age” individuals like they did their financial performance, according to a new report.

The analysis, developed by some well-known public health advocates brought together and funded by The Vitality Institute, said employers could save $217 billion to $303 billion annually, or 5 to 7 percent of total U.S. annual health spending by 2023, by adopting strategies to help Americans head off “non-communicable” diseases like cancer, diabetes, cardiovascular and respiratory issues as well as mental health.

To improve, the report’s authors say companies should be reporting health metrics like BMI and other employee health statuses just like they regularly report earnings and how an increasing number of companies report sustainability. Corporations should be required to integrate health metrics into their annual reporting by 2025, the Vitality Institute said. A link to the entire report and its recommendations is here. 

“Companies should consider the health of their employees as one of their greatest assets,” said Derek Yach, executive director of the Vitality Institute, a New York-based organization funded by South Africa’s largest health insurance company, Discovery Limited.

Those involved in the report say its recommendations come at a time the Affordable Care Act and employers emphasize wellness as a way to improve quality and reduce costs.

“Healthy workers are more productive, resulting in improved financial performance,” Yach said. “We’re calling on corporations to take accountability and start reporting health metrics in their financial and sustainability reports.  We believe this will positively impact the health of both employees and the corporate bottom line.”

The Institute brought together a commission linked here that includes some executives from the health care industry and others who work in academia and business. Commissioners came from Microsoft (MSFT);  the Robert Wood Johnson Foundation; drug and medical device giant Johnson & Johnson (JNJ); health insurer Humana (HUM); and the U.S. Department of Health and Humana Services.

The Vitality Institute said up to 80 percent of non-communicable diseases can be prevented through existing “evidence-based methods” and its report encourages the nation’s policymakers and legislative leaders to increase federal spending on prevention science at least 10 percent by 2017.

“Preventable chronic diseases such as lung cancer, diabetes and heart disease are forcing large numbers of people to exit the workforce prematurely due to their own poor health or to care for sick relatives,” said William Rosenzweig, chair of the Vitality Institute Commission and an executive at Physic Ventures, which invests in health and sustainability projects. “Yet private employers spend less than two percent of their total health budgets on prevention.  This trend will stifle America’s economic growth for decades to come unless health is embraced as a core value in society.”

Google Ventures – moving medicine out of the dark ages

Duke story about direct monkey brain implants that allow the control of more than two arms.

Great take on dealing with lagging regulation:

“You shouldn’t ignore the laws. But if you worry as an investor about, “Oh, you shouldn’t invest in any personal genomics companies because there’s a lot of regulations that need to be updated.” Well, you won’t do anything innovative.”

So yes, absolutely, the regulations need to catch up with reality. I think as the outcomes of the science with Foundation Medicine, 23andMe, etc., start to become important to people and to patients, people will demand that change. And that’s how it happens.

http://recode.net/2014/06/21/google-ventures-bill-maris-on-moving-medicine-out-of-the-dark-ages/

 

Venture capital funding for the life sciences sector dropped by $5 billion from 2008 to 2012 and was basically flat last year, according to market reports. But the search giant’s venture arm, established in 2009, has steadily plugged money into companies throughout the space, including: 23andMe, Adimab, DNANexus, Doctor on Demand, Foundation Medicine,Flatiron Health, iPierian, One Medical Group, Predilytics, Rani Therapeutics, SynapDx and Transcriptic.

Some of the bets have started to pay off. Foundation Medicine raised $100 million in an initial public offering in 2013. Earlier this year, Bristol-Myers Squibb bought portfolio company iPierian in a deal that could be worth up to $725 million.

The focus on the space at least in part reflects the background of Google Ventures’Managing Partner Bill Maris. He studied neuroscience at Middlebury College and neurobiology at Duke University. In his early career, he was the health care portfolio manager at Swedish investment firm Investor AB.

Maris also took a lead role in the creation of Calico late last year, a Google-backed company focused on delaying aging and the diseases that come with it. (Google has declined to discuss the company, which is run by Genentech Chairman Arthur Levinson.)


“Medicine needs to come out of the dark ages now.”

Bill Maris, managing partner, Google Ventures


Google Ventures generally isn’t taking the old biotech route, betting on companies somewhere along the winding path of developing drugs that may — but probably won’t — someday earn Food and Drug Administration approval. Rather, the firm is focused on companies leveraging the increasingly powerful capacities of computer science, including big data, cloud processing and genomic sequencing, to improve diagnostics or treatments.

In the second part of my two-part interview, which has been edited for space and clarity, Maris discusses the promise of these tools for medicine as well as what’s still standing in the way.

Re/code: Looking through your health-care investments, there’s 23andMe, DNA Nexus, Foundation Medicine, Flatiron. To the degree there’s a common theme, it seems these are all big data plays, using a lot of information and smart algorithms to make advancements in medical research or hit upon more effective treatments. Is that part of your investment philosophy?

Maris: I used to be a health-care investor a long time ago in the public markets. One thing I learned that we tried to apply here is that investing in small molecules, trying to invest in the next treatment, there’s an element of gambling to that.

I’m glad that people started those companies and I’m glad that they have people who specialize in investing in them. But that’s not our specialty, because you have to build a portfolio to make a success overall.

What we try to put into our practice is “invest in what we know,” which is where health care meets technology. In some sense, almost all companies these days need to be big data companies.

Bill Maris, managing director, Google Ventures

Especially when you get around genomics or, like Flatiron, looking for insights across vast amounts of oncology data. These are by definition big data companies that couldn’t have existed 10 or 15 years ago.

Take Foundation Medicine. The tools didn’t exist to actually genotype quickly the way that we can today, and in 10 years it will be even more advanced. So by necessity the companies we’re investing in are in that space, because that’s the forefront.

Clinicians treating patients based on “if you present with these symptoms, I’m going to treat you based on the knowledge in my head?” Those days are either disappearing or will soon disappear, I hope. We can get much better outcomes from people if we understand the genetic basis of the exact cancer that they have, what interventions might be most effective against it, what’s worked in the past and what hasn’t. I think that’s where the future of health care is.

So yes, lots of these are big data companies, in that sense. But that’s a catchphrase, they’re more than that. They’re data-informed companies that are trying to build businesses that are commercially important and, in this case, relevant to patients. That means they’ll get better outcomes, you’ll live longer and be healthier.

Medicine needs to come out of the Dark Ages now.

There is a unique challenge when it comes to data and medicine. Either you have a lot of information that is stored away in paper filing cabinets in doctors’ offices, or you’ve got companies that did studies decades ago that might be of use but they’re either not digitized or they’re holding on to them as intellectual property. So while there’s this great potential, it’s actually really hard to get at it. Can you talk a bit about what needs to happen technologically?

Of course it’s difficult. If it were easy it would be done by now, there would be nothing remarkable about what Nat [Turner] and Zach [Weinberg] are doing at Flatiron. The fact that it’s difficult is what makes it something an entrepreneur needs to tackle — and this isn’t unique, right?

All the information in the world has been pretty dispersed, but Google’s mission has been to organize it and make it universally accessible. That’s kind of a crazy mission and they’re doing okay at it. It takes people with a vision to say, “We’re going to try to organize this and make it accessible to people.” When we do those things, good things will result from that.

Maybe it takes a generation, because doctors will start using the system. Or maybe it just takes one big push, where we’re just going to go into clinicians’ offices and help them get all the data organized and put into electronic formats. Once you’ve done it one time you can gain an infinite number of insights to help your patients, so there’s a good motivation to do that.

Organizing healthcare information is a daunting task, but it is not an impossible task. We’ve had people walk on the moon. This is a lot more doable.

I want to ask about 23andMe. We’ve seen a handful of companies in that space that have closed or haven’t gone anywhere, and 23andMe obviously hit a big wall with the FDA last year.

I don’t know what you’re talking about.

Yeah, I read it somewhere. But that was a big part of their business, can you talk about what their ongoing prospects are and what direction they could steer in?

Yeah, as I understand it, the heredity product is still available and we see big businesses being built there, like Ancestry.com and others.

At the same time, their vision is bigger than that. They’re at an impasse with the FDA right now, but no one has thrown up their hands. Communication is ongoing, they’re trying to work that out, we’re dedicated to trying to resolve that roadblock. And we think it’s a product that is of value to people, so they can look at and understand their own genomic information.

I think the company’s prospects are great, I’ve known [co-founder] Anne [Wojcicki] for almost 20 years now, and she’s nothing if not focused, dedicated and motivated. She’s a believer in this. I think the company has been a little bit ahead of its time.

It’s inevitable that everyone will eventually be genetically sequenced because it’s going to be really important to their health care, to understanding their future and what they’re at risk for. If you believe that, then you believe that there’s probably a big business to be built here because someone has to deliver that information.

So we have a lot of faith in the team.

Taking that case — and given that health care and medical research is moving in this digital direction — do you think there are some regulatory shifts that need to take place?

I think the laws need to catch up with science and reality, and the law is never good at that. It’s always slow.

I mean, look at the patent office. I just saw a patent that Smucker’s has for a peanut butter and jelly sandwich. It’s sort of crazy.

Look at Uber and its regulatory challenges, taxi and limousine commissions trying to stop Uber. When you sit with my job — which is a really fun job to do, kind of a judge at a science fair — it’s really important to look at the technology and how it might benefit people, and not worry about the bureaucracies that might try to impede that.

At the end of the day, what always happens is, the right products for society and the people get out there.

You shouldn’t ignore the laws. But if you worry as an investor about, “Oh, you shouldn’t invest in any personal genomics companies because there’s a lot of regulations that need to be updated.” Well, you won’t do anything innovative.


RELATED ARTICLE

 

So yes, absolutely, the regulations need to catch up with reality. I think as the outcomes of the science with Foundation Medicine, 23andMe, etc., start to become important to people and to patients, people will demand that change. And that’s how it happens.

You studied neuroscience and neurobiology. What are some exciting developments you’re seeing in your own area?

I also think we’re just coming out of these Dark Ages in neuroscience. The forefront of neuroscience is (he points to parts of his head), “Well, this is the learning area, this is memory, this is where the right arm is controlled.” That’s not really how the brain works, it’s this cloud-based understanding.

I forget which neuroscientist said this, but you essentially have a Jennifer Aniston neuron. There are certain pathways in your brain that remember who that is. The more you fill up your brain with those things, the more neurons get used up.

So we’re getting closer to a point, and there are some folks at MIT working on this and other places as well, to really understanding the wiring of the brain. What makes it a whole, what causes consciousness. It’s not just that these cloudy regions all talk to each other.

You can’t do anything without a map. Until you can diagnose something you can never cure it, you can’t understand it. It’s hard to get from here to there without a map. So the first thing to do is to build a model.

When you can map an entire human brain, then you can really understand how it all works.

We don’t even know if everything gets recorded in your brain and your brain is just really good at controlling noise, where it’s just filtering out a bunch of things that you don’t need to think about because you’d just be overloaded. So there are these fundamental questions of neuroscience we just now have the tools to understand.

It’s so far behind, it’s so underfunded, in a way. We as a people and a country spend a lot of money on a lot of things. But we all walk around with this thing in our head and we have no understanding of how it actually works.

Machine-brain interfaces are a way to understand that. There’s a guy at Duke named Miguel Nicolelis, who I worked with and who comes out here every once in a while. He does work where he implants electrodes into brains and he’s now got monkeys who can move cursors on a screen [with virtual arms] and they get a reward of orange juice. Then he thought, “Well, why is the monkey just limited to one [virtual arm]? Maybe I could teach them to move three at once, or four.”

What we are learning from that is, well, we have two legs and two arms, but your brain is actually capable of operating four or six of them if you had them. There’s so much potential.

Here’s what the monkey saw in that experiment:

an idea of earth shattering significance

ok.

been looking for alignment between a significant industry sector and human health. it’s a surprisingly difficult alignment to find… go figure?

but I had lunch with joran laird from nab health today, and something amazing dawned on me, on the back of the AIA Vitality launch.

Life (not health) insurance is the vehicle. The longer you pay premiums, the more money they make.

AMAZING… AN ALIGNMENT!!!

This puts the pressure on prevention advocates to put their money where their mouth is.

If they can extend healthy life by a second, how many billions of dollars does that make for life insurers?

imagine, a health intervention that doesn’t actually involve the blundering health system!!?? PERFECT!!!

And Australia’s the perfect test bed given the opt out status of life insurance and superannuation.

Joran wants to introduce me to the MLC guys.

What could possibly go wrong??????

Dodgy wearables…

Dodgy wearables indiegogo pitch.

Airo gets a mention.

OK, I get it.

http://pando.com/2014/03/20/on-indiegogo-a-miracle-health-device-raises-730k-and-a-whole-load-of-red-flags/

On Indiegogo, a miracle health device crowdfunds $730k. One problem: it might be total bullshit

319462_10150807895075313_1360808361_nBY 
ON MARCH 20, 2014

healbe
It’s the stuff that crowdfunding dreams are made of.

An Indiegogo campaign for a gorgeous piece of wearable tech, shown off in a slick video with some great visuals. Speaking with a thick Russian accent, Healbe CEO Artem Shipitsyn describes what his company calls the ‘The Original 100% Automatic Body Manager.’ It’s called the ‘GoBe’ and it does everything a Fitbit can but so, so much more. Using Healbe’s “Flow” technology – pressure and impedance sensors mixed with an accelerometer – the device is capable of reading glucose levels through your skin to give an accurate calorie count of everything you’ve eaten, against all the energy we’ve burnt. Despite Shipitsyn’s accent, the device’s Indiegogo page says that the company is based in San Francisco.

“Tell it nothing. Know everything. Go be you,” the video signs off. The GoBe will be delivered by June of this year, to anyone who stumps up just $199.

This, ladies and gentlemen, is a market changer. Step right up!

And people have certainly stepped up. As of midday today, Shipitsyn’s campaign has raised $730,294 in two weeks, from 3253 backers — more than seven times its initial funding goal. Thirty-three backers have paid $1175 for a “Club Pack” including ten GoBe-s.

No shame in admitting it: I was impressed. If GoBe did what it claimed, this was the end of the Fitbit, the Up and just about every other weight loss technology.

And so, keen to be the first reporter to cover this marvelous piece of technology, I started asking questions. What I discovered was something far from the slick, bay area startup Healbe purported to be. Rather, I found a publicity shy company, operated remotely from Russia, promoting a device unsupported by any medical or scientific evidence whatsoever. One that thousands of backers have supported to the tune of almost three quarters of a million dollars, and one that Indiegogo says raises no red flags. In the exact words from an Indiegogo spokesperson: ”We have no reason to believe that this company’s Indiegogo campaign is at all fraudulent.”

[UPDATE: The day after publication, a different spokesperson for Indiegogo took issue with the idea that no red flags were ever raised by the campaign, finally confirming to us that the campaign was indeed investigated– and cleared– by Indiegogo’s usual anti-fraud methods. She declined to explain why the basic mistruths and inconsistencies we found in our reporting– which haven’t been denied by Healbe– didn’t concern Indiegogo. She also declined to explain what types of discoveries would lead Indiegogo to conclude an offering was fraudulent.]

My initial doubts were raised last week when I contacted the company’s information line and received no response. This is odd. Normally when I contact the folks behind crowdfunding campaigns, the response is prompt, and enthusiastic. The more publicity, the more money, after all.

I try again this past Monday. Finally, Meghan Donovan, from MicroArts Creative Agency in Greenland, New Hampshire replies, asking if we can talk the next day. There’s just one problem, she explains when we speak: everyone at Healbe was travelling through the end of the week. She promises to get back to me within a couple of days.

A Google search shows that the GoBe has been the subject of about two dozen press articles, but all of them either quote from the press release or the Indiegogo campaign itself. No major tech website has covered the device, and no scientists seem to be as excited as I am about its apparent medical breakthrough. Healbe might be the most press-shy successful startup on earth.

Artem Shipitsyn (also spelt as Shipitsin) and five of his six colleagues listed on the Indiegogo page – George Mikaberydze, Stanislav Povolotskiy, Michael Rubin, Eugene Sokolov, Pavel Mussel – are traceable online only in relation to this one Indiegogo campaign. Shipitsyn lists himself on the page as “a major developer of market solutions and new products for global brands such as Rostelcorn, Sberbank, L’Oreal, Valio, Reebok, Hearst Shkulev, Discovery Channel and more.” And yet on hisLinkedIn profile he lists none of that, describing himself instead as the owner, since 2004, of Iridium, a marketing company in Russia with little discernible online footprint. And now the CEO of Healbe.

Healbe’s website lists no contact details except for the email address that connected me to Donovan’s PR agency in New Hampshire. An address listed for Healbe Incorporated on an old version of its website leads to a law firm, White Summers, in Redwood City. A receptionist for White Summers confirms that Healbe is a client. The company itself is registered in Delaware. This is apparently the extent of its American infrastructure.

Meanwhile, some of GoBe’s backers are getting cold feet: requests for refunds are starting to trickle on to Healbe’s Indiegogo page, dissent is growing on the company’s Facebook and a few Redditers are getting twitchy.

Michelle MacDonald, a clinical dietician at the National Jewish Health hospital in Denver, tells me that her eyebrows were raised almost immediately when she read Healbe’s claims that, through an “algorithm,” it can work out from glucose levels in our cells what our caloric intake was. “Of course they’re claiming an algorithm, because it’s a fun word,” McDonald laughs.

The problem is, MacDonald explains, the three main nutrients that determine caloric intake are carbohydrates, protein and fats. Glucose provides only a small part of the picture. A company that invented a non-invasive way to measure glucose would be a huge hit with the treatment of diabetes. Currently, diabetes sufferers have to prick their skin and make themselves bleed. The technology is probably coming soon, MacDonald says, but when it does it will be the size of a shoebox. It will also likely involve some form of infrared light shone through the skin that will measure the fluid in interstitial cells to approximate the blood glucose level in a simple milligrams per deciliter figure. It will come from a big lab, will be huge news and make a lot of money.

“If you actually had this technology, Indiegogo would be the last channel you’d go through,” MacDonald says.

Let’s imagine that Healbe really has perfected this technology, though. Even so, MacDonald says, nothing described in the video could do what it claims to. The impedance monitor could look at hydration, the pressure monitor could examine pulse and the accelerometer could tell us about action. But none of those three things could tell you anything about glucose levels. A graphic of Healbe’s accompanying smartphone app even shows it measuring fat and carbohydrates, which is doubly ridiculous.

MacDonald takes particular umbrage at Healbe listing its chief scientist Eugene Sokolov as having a background as a rocket scientist. “I wish I was a standup comedian. I could really run with that,” she laughs. Maybe they’ve left out the key part from the video, she hedges. “But when you fail to explain it, that’s always a red flag.”

In fact there are multiple red flags.

I call Meghan Donovan back. She assures me that the GoBe is a real, working device. Her company was employed by Healbe in Fall 2013 and Shipitsyn came into the MicroArts office to film the Indiegogo video in January. He bought two models in for the video, but Donovan admits that she never saw the device in action. Shipitsyn told her that they were doing their own internal tests. But, she tells me, Healbe displayed its product at CES. That’s something.

On closer inspection, Healbe’s Indiegogo page talks about having “unveiled” the GoBe at CES. Except when I look, there’s no reference to Healbe in the CES directory of exhibiting companies in 2014.

I talk to Healbe’s industrial designer Jozeph Forakis, who has done work for Motorola and Swatch in the past. Over Skype from Italy, Forakis confirms that he has worked with Shipitsyn and Healbe for a year on several different prototypes, “the most recent of which were shown in January in CES.”

Why, then, can’t I find any reference to Healbe in the CES directory? Well, Healbe wasn’t technically at CES Forakis admits. But Shipitsyn was in Las Vegas at the time, taking meetings in his hotel room.

Forakis and Donovan are the only two people I can find who claim to have seen a GoBe in real life. Neither are willing to vouch for the science behind it.

At least Indiegogo believes in Shipitsyn. The Healbe campaign raises no red flags, a company spokesperson tells me. Indiegogo, she says, has a vested interest in security. It prides itself on its “equal opportunity, open platform… literally anyone from anywhere in the world can raise money here.”

In October last year, a Canadian company called Airo Health promised a wearable that could do the same thing as Healbe, with a slightly different technique – looking at nutrient levels in our blood by shining a light through it. The company took pre-orders through its website, but a month later refunded all of its customers. “Through conversations with others in the industry, we have come to realize that it requires further testing,” the company said in a release.

Indiegogo protects itself against fraud with an algorithm — that word again — that detects troublesome accounts, alongside human vetting and the group mentality of crowdfunding picking  out bad eggs.

Fraud is a slippery term, though. It doesn’t account for more subtle manipulations. Healbe’s Gobe activity tracker looks enough like a Fitbit that the average shopper can grasp what it is, and what it might be able to do. The automatic calorie reader claim is an advancement that we can all appreciate the significance of, but few of us can pick apart the science behind. Indiegogo can protect against an outright fraudster, but a snake oil salesman with an unproven product is a different matter. Since the beginning of recorded history, opportunists have been using impressive pitches to sell miracle health potions and devices — really the only thing that’s changed is the technology (although it used to be that if you were conned by a snake oil salesman, at least you’d end up with a pretty glass bottle. Indiegogo can’t even promise that.)

Indiegogo wants to keep these concerns inside the domain of the campaigner-funder relationship. Despite $730,000 in pledges, Indiegogo’s position is that as long as there’s a real company claiming to make something that doesn’t violate its terms of service, it has no moral or legal obligation to ensure that the GoBe is legit. All backers can do is wait until June to see if their miracle band shows up and does what it says in the video.

I was finally able to reach Shipitsyn and Healbe’s managing director George Mikaberydze this morning in Moscow, Russia, via Skype, two hours before my deadline for this piece. Their schedules had apparently become more flexible since I started asking questions.

Shipitsyn holds the device close to the camera — it seems to be the same as in the video — while Mikaberydze points to a fuzzy line on an app that, he says, breaks down his energy consumption over the last 20 minutes since he ate a Snickers bar. They were at CES, they say, as the guest of Levin Consulting, with their own meeting room. They hold up an attendee badge showing, at least, that they visited the conference.

So what about the science? Shipitsyn says that the impedance monitor in the Gobe can measure glucose by monitoring the water moving in and out of cells. Insulin opens up the cells when you eat sugar, he says. The company will publish their own clinical tests soon and are discussing with a third party clinic in America, Shipitsyn insists. They’ve slipped off the medical radar because the accuracy rates range between 80 and 90 percent. The head of Samsung Russia is apparently a huge fan.

It’s a breezy, confident pitch. Shipitsyn and Mikaberydze have a ready response to all of my concerns — the subtext being that I really ought to trust them.

But here’s the rub: I don’t. Or at least not enough to part with $199 for a device for which they haven’t yet released any clinical test results (despite their insistence that these apparently do exist) and which, right now, only exists as a demo on a screen.

I’ve jostled myself right up to the soapbox, pushed my face as close to the screen as it’s possible to get, and I still have absolutely no hard evidence that this device is any more than a smart mock up. Shipitsyn says its a miracle machine, at least one expert says it can’t possibly exist.

What I know for a fact is this: in about three weeks, Healbe will be close to three quarters of a million dollars richer, at least. Indiegogo says they have no reason to withhold the money raised, or to doubt that it will be used to deliver GoBes to three-and-a-bit thousand backers who have, presumably, weighed up the risks for themselves and decided to put their faith in Shipitsyn and his partners. Shipitsyn himself says there’s nothing to worry about, but it won’t be until at least June — plenty of time for the money to have moved from a Delaware corporation to a bank account in Moscow — before we know the truth.

Pando will keep pushing HealBe to publish their trial results and I’ll embed them in this post if and when they do. In the meantime, anyone who is inclined to bet $199 or more on a miracle weight loss device might recall the old maxim: if something seems too good to be true, it probably is.

Shipitsyn has a hell of a pitch, but my $199 is staying in my pocket.

See here for the latest updates on this story.

319462_10150807895075313_1360808361_n

James Robinson is a staff writer for PandoDaily covering hardware, advertising technology and the Internet of Things… among many other general goings on. Follow him on Twitter: @jalrobinson

Greg Ellis (ex-REA CEO) leaving for Germany

http://www.abc.net.au/radionational/programs/saturdayextra/growing-aust-business/5364200

Growing Australian business

Saturday 5 April 2014 8:05AM

One of Australia’s most creative businessmen has joined a small but definitely growing critique of our national business culture.

Greg Ellis, the outgoing Chief Executive of the REA Group – the online real estate classified business, that’s rapidly increased in value under his leadership – strongly believes that Australian business needs a lot more fresh ideas.

The Hammerbacher Quote

“The best minds of my generation are thinking about how to make people click ads… That sucks.”

 

http://www.businessweek.com/magazine/content/11_17/b4225060960537.htm

This Tech Bubble Is Different

By  

As a 23-year-old math genius one year out of Harvard, Jeff Hammerbacher arrived at Facebook when the company was still in its infancy. This was in April 2006, and Mark Zuckerberg gave Hammerbacher—one of Facebook’s first 100 employees—the lofty title of research scientist and put him to work analyzing how people used the social networking service. Specifically, he was given the assignment of uncovering why Facebook took off at some universities and flopped at others. The company also wanted to track differences in behavior between high-school-age kids and older, drunker college students. “I was there to answer these high-level questions, and they really didn’t have any tools to do that yet,” he says.

Over the next two years, Hammerbacher assembled a team to build a new class of analytical technology. His crew gathered huge volumes of data, pored over it, and learned much about people’s relationships, tendencies, and desires. Facebook has since turned these insights into precision advertising, the foundation of its business. It offers companies access to a captive pool of people who have effectively volunteered to have their actions monitored like so many lab rats. The hope—as signified by Facebook’s value, now at $65 billion according to research firm Nyppex—is that more data translate into better ads and higher sales.

After a couple years at Facebook, Hammerbacher grew restless. He figured that much of the groundbreaking computer science had been done. Something else gnawed at him. Hammerbacher looked around Silicon Valley at companies like his own, Google (GOOG), and Twitter, and saw his peers wasting their talents. “The best minds of my generation are thinking about how to make people click ads,” he says. “That sucks.”

You might say Hammerbacher is a conscientious objector to the ad-based business model and marketing-driven culture that now permeates tech. Online ads have been around since the dawn of the Web, but only in recent years have they become the rapturous life dream of Silicon Valley. Arriving on the heels of Facebook have been blockbusters such as the game maker Zynga and coupon peddler Groupon. These companies have engaged in a frenetic, costly war to hire the best executives and engineers they can find. Investors have joined in, throwing money at the Web stars and sending valuations into the stratosphere. Inevitably, copycats have arrived, and investors are pushing and shoving to get in early on that action, too. Once again, 11 years after the dot-com-era peak of the Nasdaq, Silicon Valley is reaching the saturation point with business plans that hinge on crossed fingers as much as anything else. “We are certainly in another bubble,” says Matthew Cowan, co-founder of the tech investment firm Bridgescale Partners. “And it’s being driven by social media and consumer-oriented applications.”

There’s always someone out there crying bubble, it seems; the trick is figuring out when it’s easy money—and when it’s a shell game. Some bubbles actually do some good, even if they don’t end happily. In the 1980s, the rise of Microsoft (MSFT), Compaq (HPQ), and Intel (INTC) pushed personal computers into millions of businesses and homes—and the stocks of those companies soared. Tech stumbled in the late 1980s, and the Valley was left with lots of cheap microprocessors and theories on what to do with them. The dot-com boom was built on infatuation with anything Web-related. Then the correction began in early 2000, eventually vaporizing about $6 trillion in shareholder value. But that cycle, too, left behind an Internet infrastructure that has come to benefit businesses and consumers.

 

This time, the hype centers on more precise ways to sell. At Zynga, they’re mastering the art of coaxing game players to take surveys and snatch up credit-card deals. Elsewhere, engineers burn the midnight oil making sure that a shoe ad follows a consumer from Web site to Web site until the person finally cracks and buys some new kicks.

This latest craze reflects a natural evolution. A focus on what economists call general-purpose technology—steam power, the Internet router—has given way to interest in consumer products such as iPhones and streaming movies. “Any generation of smart people will be drawn to where the money is, and right now it’s the ad generation,” says Steve Perlman, a Silicon Valley entrepreneur who once sold WebTV to Microsoft for $425 million and is now running OnLive, an online video game service. “There is a goodness to it in that people are building on the underpinnings laid by other people.”

So if this tech bubble is about getting shoppers to buy, what’s left if and when it pops? Perlman grows agitated when asked that question. Hands waving and voice rising, he says that venture capitalists have become consumed with finding overnight sensations. They’ve pulled away from funding risky projects that create more of those general-purpose technologies—inventions that lay the foundation for more invention. “Facebook is not the kind of technology that will stop us from having dropped cell phone calls, and neither is Groupon or any of these advertising things,” he says. “We need them. O.K., great. But they are building on top of old technology, and at some point you exhaust the fuel of the underpinnings.”

And if that fuel of innovation is exhausted? “My fear is that Silicon Valley has become more like Hollywood,” says Glenn Kelman, chief executive officer of online real estate brokerage Redfin, who has been a software executive for 20 years. “An entertainment-oriented, hit-driven business that doesn’t fundamentally increase American competitiveness.”

Hammerbacher quit Facebook in 2008, took some time off, and then co-founded Cloudera, a data-analysis software startup. He’s 28 now and speaks with the classic Silicon Valley blend of preternatural self-assurance and save-the-worldism, especially when he gets going on tech’s hottest properties. “If instead of pointing their incredible infrastructure at making people click on ads,” he likes to ask, “they pointed it at great unsolved problems in science, how would the world be different today?” And yet, other than the fact that he bailed from a sweet, pre-IPO gig at the hottest ad-driven tech company of them all, Hammerbacher typifies the new breed of Silicon Valley advertising whiz kid. He’s not really a programmer or an engineer; he’s mostly just really, really good at math.

Hammerbacher grew up in Indiana and Michigan, the son of a General Motors (GM) assembly-line worker. As a teenager, he perfected his curve ball to the point that college scouts from the University of Michigan and Harvard fought for his services. “I was either going to be a baseball player, a poet, or a mathematician,” he says. Hammerbacher went with math and Harvard. Unlike one of his more prominent Harvard acquaintances—Facebook co-founder Mark Zuckerberg—Hammerbacher graduated. He took a job at Bear Stearns.

On Wall Street, the math geeks are known as quants. They’re the ones who create sophisticated trading algorithms that can ingest vast amounts of market data and then form buy and sell decisions in milliseconds. Hammerbacher was a quant. After about 10 months, he got back in touch with Zuckerberg, who offered him the Facebook job in California. That’s when Hammerbacher redirected his quant proclivities toward consumer technology. He became, as it were, a Want.

 

At social networking companies, Wants may sit among the computer scientists and engineers, but theirs is the central mission: to poke around in data, hunt for trends, and figure out formulas that will put the right ad in front of the right person. Wants gauge the personality types of customers, measure their desire for certain products, and discern what will motivate people to act on ads. “The most coveted employee in Silicon Valley today is not a software engineer. It is a mathematician,” says Kelman, the Redfin CEO. “The mathematicians are trying to tickle your fancy long enough to see one more ad.”

Sometimes the objective is simply to turn people on. Zynga, the maker of popular Facebook games such as CityVille and FarmVille, collects 60 billion data points per day—how long people play games, when they play them, what they’re buying, and so forth. The Wants (Zynga’s term is “data ninjas”) troll this information to figure out which people like to visit their friends’ farms and cities, the most popular items people buy, and how often people send notes to their friends. Discovery: People enjoy the games more if they receive gifts from their friends, such as the virtual wood and nails needed to build a digital barn. As for the poor folks without many friends who aren’t having as much fun, the Wants came up with a solution. “We made it easier for those players to find the parts elsewhere in the game, so they relied less on receiving the items as gifts,” says Ken Rudin, Zynga’s vice-president for analytics.

These consumer-targeting operations look a lot like what quants do on Wall Street. A Want system, for example, might watch what someone searches for on Google, what they write about in Gmail, and the websites they visit. “You get all this data and then build very rapid decision-making models based on their history and commercial intent,” says Will Price, CEO of Flite, an online ad service. “You have to make all of those calculations before the Web page loads.”

Ultimately, ad-tech companies are giving consumers what they desire and, in many cases, providing valuable services. Google delivers free access to much of the world’s information along with free maps, office software, and smartphone software. It also takes profits from ads and directs them toward tough engineering projects like building cars that can drive themselves and sending robots to the moon. The Era of Ads also gives the Wants something they yearn for: a ticket out of Nerdsville. “It lets people that are left- brain leaning expand their career opportunities,” says Doug Mack, CEO of One Kings Lane, a daily deal site that specializes in designer goods. “People that might have been in engineering can go into marketing, business development, and even sales. They can get on the leadership track.” And while the Wants plumb the depths of the consumer mind and advance their own careers, investors are getting something too, at least on paper: almost unimaginable valuations. Just since the fourth quarter, Zynga has risen 81 percent in value, to a cool $8 billion, according to Nyppex.

No one is suggesting that the top tier of ad-centric companies—Facebook, Google—is going down should the bubble pop. As for the next tier or two down, where a profusion of startups is piling into every possible niche involving social networking and ads—the fate of those companies is anybody’s guess. Among the many unveilings in March, one stood out: An app called Color, made by a seven-month-old startup of the same name. Color lets people take and store their pictures. More than that, it uses geolocation and ambient-noise-matching technology to figure out where a person is and then automatically shares his photos with other nearby people and vice versa. People at a concert, for example, could see photos taken by all the other people at that concert. The same goes for birthday parties, sporting events, or a night out at a bar. The app also shares photos among your friends in the Color social network, so you can see how Jane is spending her vacation or what John ate for breakfast, if he bothered to take a photo of it.

 

Whether Color ends up as a profitable app remains to be seen. The company has yet to settle on a business model, although its executives say it’ll probably incorporate some form of local advertising. Figuring out all those location-based news feeds on the fly requires serious computational power, and that part of the business is headed by Color’s math wizard and chief product officer, DJ Patil.

Patil’s Silicon Valley pedigree is impeccable. His father, Suhas Patil, emigrated from India and founded the chip company Cirrus Logic (CRUS). DJ struggled in high school, did some time at a junior college, and through force of will decided to get good at math. He made it into the University of California at San Diego, where he took every math course he could. He became a theoretical math guru and went on to research weather patterns, the collapse of sardine populations, the formation of sand dunes, and, during a stint for the Defense Dept., the detection of biological weapons in Central Asia. “All of these things were about how to use science and math to achieve these broader means,” Patil says. Eventually, Silicon Valley lured him back. He went to work for eBay (EBAY), creating an antifraud system for the retail site. “I took ideas from the bioweapons threat anticipation project,” he says. “It’s all about looking at a network and your social interactions to find out if you’re good or bad.”

Patil, 36, agonized about his jump away from the one true path of Silicon Valley righteousness, doing gritty research worthy of his father’s generation. “There is a time in life where that kind of work is easy to do and a time when it’s hard to do,” he says. “With a kid and a family, it was getting hard.”

Having gone through a similar self-inquiry, Hammerbacher doesn’t begrudge talented technologists like Patil for plying their trade in the glitzy land of networked photo sharing. The two are friends, in fact; they’ve gotten together to talk about data and the challenges in parsing vast quantities of it. At social networking companies, Hammerbacher says, “there are some people that just really buy the mission—connecting people. I don’t think there is anything wrong with those people. But it just didn’t resonate with me.”

After quitting Facebook in 2008, Hammerbacher surveyed the science and business landscape and saw that all types of organizations were running into similar problems faced by consumer Web companies. They were producing unprecedented amounts of information—DNA sequences, seismic data for energy companies, sales information—and struggling to find ways to pull insights out of the data. Hammerbacher and his fellow Cloudera founders figured they could redirect the analytical tools created by Web companies to a new pursuit, namely bringing researchers and businesses into the modern age.

Cloudera is essentially trying to build a type of operating system, à la Windows, for examining huge stockpiles of information. Where Windows manages the basic functions of a PC and its software, Cloudera’s technology helps companies break data into digestible chunks that can be spread across relatively cheap computers. Customers can then pose rapid-fire questions and receive answers. But instead of asking what a group of friends “like” the most on Facebook, the customers ask questions such as, “What gene do all these cancer patients share?”

Eric Schadt, the chief scientific officer at Pacific Biosciences, a maker of genome sequencing machines, says new-drug discovery and cancer cures depend on analytical tools. Companies using Pacific Bio’s machines will produce mountains of information every day as they sequence more and more people. Their goal: to map the complex interactions among genes, organs, and other body systems and raise questions about how the interactions result in certain illnesses—and cures. The scientists have struggled to build the analytical tools needed to perform this work and are looking to Silicon Valley for help. “It won’t be old school biologists that drive the next leaps in pharma,” says Schadt. “It will be guys like Jeff who understand what to do with big data.”

Even if Cloudera doesn’t find a cure for cancer, rid Silicon Valley of ad-think, and persuade a generation of brainiacs to embrace the adventure that is business software, Price argues, the tech industry will have the same entrepreneurial fervor of yesteryear. “You can make a lot of jokes about Zynga and playing FarmVille, but they are generating billions of dollars,” the Flite CEO says. “The greatest thing about the Valley is that people come and work in these super-intense, high-pressure environments and see what it takes to create a business and take risk.” A parade of employees has left Google and Facebook to start their own companies, dabbling in everything from more ad systems to robotics and publishing. “It’s almost a perpetual-motion machine,” Price says.

Perpetual-motion machines sound great until you remember that they don’t exist. So far, the Wants have failed to carry the rest of the industry toward higher ground. “It’s clear that the new industry that is building around Internet advertising and these other services doesn’t create that many jobs,” says Christophe Lécuyer, a historian who has written numerous books about Silicon Valley’s economic history. “The loss of manufacturing and design knowhow is truly worrisome.”

Dial back the clock 25 years to an earlier tech boom. In 1986, Microsoft, Oracle (ORCL), and Sun Microsystems went public. Compaq went from launch to the Fortune 500 in four years—the quickest run in history. Each of those companies has waxed and waned, yet all helped build technology that begat other technologies. And now? Groupon, which e-mails coupons to people, may be the fastest-growing company of all time. Its revenue could hit $4 billion this year, up from $750 million last year, and the startup has reached a valuation of $25 billion. Its technological legacy is cute e-mail.

There have always been foundational technologies and flashier derivatives built atop them. Sometimes one cycle’s glamour company becomes the next one’s hard-core technology company; witness Amazon.com’s (AMZN) transformation over the past decade from mere e-commerce powerhouse to e-commerce powerhouse and purveyor of cloud-computing capabilities to other companies. Has the pendulum swung too far? “It’s a safe bet that sometime in the next 20 months, the capital markets will close, the music will stop, and the world will look bleak again,” says Bridgescale Partners’ Cowan. “The legitimate concern here is that we are not diversifying, so that we have roots to fall back on when we enter a different part of the cycle.”

Vance_190
Vance is a technology writer for Bloomberg Businessweek in Palo Alto, Calif. Follow him on Twitter @valleyhack.